Risk factors
Immuneering (IMRX) risk factors
Item 1A of every Immuneering Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks7 dropped11 reworded
Immuneering updated product references from IMM-1-104 and IMM-6-415 to atebimetinib and disclosed a reduction in full-time employees to 53.
Filed Mar 06, 2026 - FY2024 10-K risk factors85 risks
Immunereing faces going concern doubts and needs substantial capital to fund its clinical-stage oncology pipeline. The company relies heavily on its unproven DCT platform and MAPK pathway targeting therapies like IMM-1-104 and IMM-6-415. Operations carry high regulatory, manufacturing, and third-party dependency risks without any commercialized products to date.
Filed Mar 20, 2025